Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Interact Cardiovasc Thorac Surg ; 24(4): 514-520, 2017 04 01.
Article in English | MEDLINE | ID: mdl-28077510

ABSTRACT

Objectives: Reoperative procedure for the treatment of a failed mitral bioprosthesis is associated with considerable risk. In some cases, mortality is high and might contraindicate the benefit of the procedure. The minimally invasive valve-in-valve (ViV) transcatheter mitral valve implant offers an alternative less-invasive approach, reducing morbidity and mortality. The objective of this paper was to evaluate the mitral ViV approach using the Braile Inovare prosthesis. Methods: The transcatheter balloon-expandable Braile Inovare prosthesis was used in 12 cases. Procedures were performed in a hybrid operating room, under fluoroscopic and echocardiographic control. Through left minithoracotomy, the prostheses were implanted through the cardiac apex. Serial echocardiographic and clinical examinations were performed. Follow-up varied from 1 to 30 months. Results: A total of 12 transapical mitral ViV procedures were performed. Patients had a mean age of 61.6 ± 9.9 years and 92% were women. Mean logistic EuroSCORE was 20.1%. Successful valve implantation was possible in all cases. In one case, a right lateral thoracotomy was performed for the removal of an embolized prosthesis. There was no operative mortality. Thirty-day mortality was 8.3%. Ejection fraction was preserved after the implant (66.7%; 64.8%; P = 0.3). The mitral gradient showed a significant reduction (11 mmHg; 6 mmHg; P < 0.001). Residual mitral regurgitation was not present. There was no left ventricular outflow tract obstruction. Conclusions: The mitral ViV implant in a failed bioprosthesis is an effective procedure. This possibility might alter prosthesis selection in the future initial surgical prosthesis selection, favouring bioprostheses. Further large trials should explore its safety.


Subject(s)
Bioprosthesis , Heart Valve Diseases/surgery , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis , Mitral Valve , Aged , Cardiac Catheterization , Female , Humans , Male , Middle Aged , Prosthesis Design , Reoperation , Risk Factors , Time Factors , Treatment Outcome
2.
J Thromb Thrombolysis ; 38(4): 510-6, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24671733

ABSTRACT

Pharmacoinvasive treatment is an acceptable alternative for patients with ST-segment elevation myocardial infarction (STEMI) in developing countries. The present study evaluated the influence of gender on the risks of death and major adverse cardiovascular events (MACE) in this population. Seven municipal emergency rooms and the Emergency Mobile Healthcare Service in São Paulo treated STEMI patients with tenecteplase. The patients were subsequently transferred to a tertiary teaching hospital for early (<24 h) coronary angiography. A total of 469 patients were evaluated [329 men (70.1%)]. Compared to men, women had more advanced age (60.2 ± 12.3 vs. 56.5 ± 11 years; p = 0.002); lower body mass index (BMI; 25.85 ± 5.07 vs. 27.04 ± 4.26 kg/m2; p = 0.009); higher rates of hypertension (70.7 vs. 59.3%, p = 0.02); higher incidence of hypothyroidism (20.0 vs. 5.5%; p < 0.001), chronic renal failure (10.0 vs. 8.8%; p = 0.68), peripheral vascular disease (PVD; 19.3 vs. 4.3%; p = 0.03), and previous history of stroke (6.4 vs. 1.3%; p = 0.13); and higher thrombolysis in myocardial infarction risk scores (40.0 vs. 23.7%; p < 0.001). The overall in-hospital mortality and MACE rates for women versus men were 9.3 versus 4.9% (p = 0.07) and 12.9 versus 7.9% (p = 0.09), respectively. By multivariate analysis, diabetes (OR 4.15; 95% CI 1.86-9.25; p = 0.001), previous stroke (OR 4.81; 95% CI 1.49-15.52; p = 0.009), and hypothyroidism (OR 3.75; 95% CI 1.44-9.81; p = 0.007), were independent predictors of mortality, whereas diabetes (OR 2.05; 95% CI 1.03-4.06; p = 0.04), PVD (OR 2.38; 95% CI 0.88-6.43; p = 0.08), were predictors of MACE. In STEMI patients undergoing pharmacoinvasive strategy, mortality and MACE rates were twice as high in women; however, this was due to a higher prevalence of risk factors and not gender itself.


Subject(s)
Emergency Medical Services , Fibrinolytic Agents/administration & dosage , Myocardial Infarction/drug therapy , Myocardial Infarction/mortality , Sex Characteristics , Tissue Plasminogen Activator/administration & dosage , Aged , Emergency Medical Services/trends , Female , Humans , Male , Middle Aged , Mortality/trends , Myocardial Infarction/diagnosis , Retrospective Studies , Risk Factors , Tenecteplase
3.
Clinics ; 68(12): 1516-1520, dez. 2013. tab, graf
Article in English | LILACS | ID: lil-697703

ABSTRACT

OBJECTIVES: To identify predictors of in-hospital mortality in patients with acute myocardial infarction undergoing pharmacoinvasive treatment. METHODS: This was an observational, prospective study that included 398 patients admitted to a tertiary center for percutaneous coronary intervention within 3 to 24 hours after thrombolysis with tenecteplase. ClinicalTrials.gov: NCT01791764 RESULTS: The overall in-hospital mortality rate was 5.8%. Compared with patients who survived, patients who died were more likely to be older, have higher rates of diabetes and chronic renal failure, have a lower left ventricular ejection fraction, and demonstrate more evidence of heart failure (Killip class III or IV). Patients who died had significantly lower rates of successful thrombolysis (39% vs. 68%; p = 0.005) and final myocardial blush grade 3 (13.0% vs. 61.9%; p<0.0001). Based on the multivariate analysis, the Global Registry of Acute Coronary Events score (odds ratio 1.05, 95% confidence interval (CI) 1.02-1.09; p = 0.001), left ventricular ejection fraction (odds ratio 0.9, 95% CI 0.89-0.97; p = 0.001), and final myocardial blush grade of 0-2 (odds ratio 8.85, 95% CI 1.34-58.57; p = 0.02) were independent predictors of mortality. CONCLUSIONS: In this prospective study that evaluated patients with ST-segment elevation myocardial infarction treated by a pharmacoinvasive strategy, the in-hospital mortality rate was 5.8%. The Global Registry of Acute Coronary Events score, left ventricular ejection fraction, and myocardial blush were independent predictors of mortality in this high-risk group of acute coronary syndrome patients. .


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Hospital Mortality , Myocardial Infarction/drug therapy , Myocardial Infarction/mortality , Brazil , Fibrinolytic Agents/therapeutic use , Logistic Models , Predictive Value of Tests , Prospective Studies , Risk Factors , Stroke Volume/physiology , Time Factors , Treatment Outcome , Tertiary Care Centers/statistics & numerical data , Thrombolytic Therapy/methods , Tissue Plasminogen Activator/therapeutic use
5.
Clinics (Sao Paulo) ; 68(12): 1516-20, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24473509

ABSTRACT

OBJECTIVES: To identify predictors of in-hospital mortality in patients with acute myocardial infarction undergoing pharmacoinvasive treatment. METHODS: This was an observational, prospective study that included 398 patients admitted to a tertiary center for percutaneous coronary intervention within 3 to 24 hours after thrombolysis with tenecteplase. ClinicalTrials.gov: NCT01791764 RESULTS: The overall in-hospital mortality rate was 5.8%. Compared with patients who survived, patients who died were more likely to be older, have higher rates of diabetes and chronic renal failure, have a lower left ventricular ejection fraction, and demonstrate more evidence of heart failure (Killip class III or IV). Patients who died had significantly lower rates of successful thrombolysis (39% vs. 68%; p = 0.005) and final myocardial blush grade 3 (13.0% vs. 61.9%; p<0.0001). Based on the multivariate analysis, the Global Registry of Acute Coronary Events score (odds ratio 1.05, 95% confidence interval (CI) 1.02-1.09; p = 0.001), left ventricular ejection fraction (odds ratio 0.9, 95% CI 0.89-0.97; p = 0.001), and final myocardial blush grade of 0-2 (odds ratio 8.85, 95% CI 1.34-58.57; p = 0.02) were independent predictors of mortality. CONCLUSIONS: In this prospective study that evaluated patients with ST-segment elevation myocardial infarction treated by a pharmacoinvasive strategy, the in-hospital mortality rate was 5.8%. The Global Registry of Acute Coronary Events score, left ventricular ejection fraction, and myocardial blush were independent predictors of mortality in this high-risk group of acute coronary syndrome patients.


Subject(s)
Hospital Mortality , Myocardial Infarction/drug therapy , Myocardial Infarction/mortality , Aged , Brazil , Female , Fibrinolytic Agents/therapeutic use , Humans , Logistic Models , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Risk Factors , Stroke Volume/physiology , Tenecteplase , Tertiary Care Centers/statistics & numerical data , Thrombolytic Therapy/methods , Time Factors , Tissue Plasminogen Activator/therapeutic use , Treatment Outcome
6.
Eur J Cardiothorac Surg ; 41(3): 696-8, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22345189

ABSTRACT

Tricuspid valve disease is not uncommon. Some patients with tricuspid valve disease require tricuspid replacement with bioprosthesis and, over time, may require re-interventions. Transcatheter tricuspid valve-in-valve approach has emerged as an alternative to treat dysfunctional bioprosthesis. In this article, we report a case of a patient with four previous cardiac interventions presenting with tricuspid bioprosthesis dysfunction. The patient was treated with the transcatheter transatrial tricuspid valve-in-valve procedure. The procedure was successful with no residual leakage and a non-significant mean gradient. The patient recovered well and was discharged in 1 week. The procedure is a feasible alternative for high-risk patients. Selection and postoperative care are crucial for the outcome.


Subject(s)
Heart Valve Diseases/surgery , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis , Tricuspid Valve/surgery , Aged , Bioprosthesis , Cardiac Catheterization/methods , Feasibility Studies , Female , Humans , Minimally Invasive Surgical Procedures/methods , Prosthesis Design , Prosthesis Failure , Reoperation/methods
8.
Rev Bras Cir Cardiovasc ; 26(3): 338-47, 2011.
Article in English, Portuguese | MEDLINE | ID: mdl-22086569

ABSTRACT

OBJECTIVE: Aortic valve replacement is a routine procedure with acceptable risk, but in some cases, such risk can justify contraindication. Minimally invasive transcatheter aortic valve implantation has emerged as an alternative, with lower morbidity and mortality. The aim of this study was clinical, safety and efficacy assessment. METHODS: Thirty-three high risk patients underwent transcatheter balloon expandable aortic valve implantation. Mean Logistic EuroScore risk was 39.30% and STS score 30.28%. Eight patients presented with dysfunctional bioprosthesis, remaining ones presented calcified aortic stenosis. Procedures were performed in a hybrid OR under fluoroscopic and echocardiography guidance. Using a left minithoracotomy the prosthesis were implanted trough the ventricular apex under rapid ventricular pacing or hemorrhagic shock. Echocardiographic and angiographic controls were performed. RESULTS: Implant was feasible in 30 cases. Three conversions occured. There was only one case of operative death. Median transvalvular aortic gradient reduced from 43.58 mmHg to 10.54 mmHg. Left ventricular function improved in the first 7 postoperative days. Paravalvular aortic regurgitation was mild and present in 30.30%. One case presented major vascular complication and another one permanent pacemaker implant. One major stroke case occurred. Overall 30-day mortality was 18.18%. CONCLUSION: The transapical implantation of catheter mounted bioprosthesis is a safe procedure with acceptable midterm results. Long term follow-up with increased sample power is mandatory in order to access hemodynamic, life quality and survival.


Subject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Calcinosis/surgery , Cardiac Catheterization/adverse effects , Heart Valve Prosthesis Implantation/methods , Adult , Aged , Aged, 80 and over , Aortic Valve Stenosis/physiopathology , Brazil , Calcinosis/physiopathology , Cardiac Catheterization/methods , Feasibility Studies , Female , Heart Valve Prosthesis Implantation/mortality , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Risk Assessment/methods , Treatment Outcome
9.
Rev. bras. cir. cardiovasc ; 26(3): 338-347, jul.-set. 2011.
Article in Portuguese | LILACS | ID: lil-624514

ABSTRACT

OBJETIVO: A troca valvar aórtica é procedimento rotineiro com risco aceitável. Em alguns casos, a mortalidade é elevada, contraindicando o procedimento. O implante minimamente invasivo transcateter de valva aórtica parece ser alternativa, reduzindo a morbimortalidade. A avaliação dos resultados clínicos, segurança e eficácia do procedimento são o objetivo desse estudo. MÉTODOS: Uma prótese transcateter, balão expansível foi utilizada em 33 casos de alto risco. EuroScore médio foi de 39,30% e STS score de 30,28%. Oito pacientes apresentavam disfunção de bioprótese e o restante, estenose aórtica calcificada. Os procedimentos foram realizados em ambiente cirúrgico híbrido, sob controle ecocardiográfico e fluoroscópico. Através de minitoracotomia esquerda, as próteses foram implantadas pelo ápice ventricular, sob estimulação de alta frequência ou choque hemorrágico. Foram realizados controles clínicos e ecocardiográficos. RESULTADOS: A correta liberação da prótese foi possível em 30 casos. Três conversões ocorreram. A mortalidade operatória foi de um caso e a mortalidade em 30 dias, 18,18%. O gradiente médio reduziu de 43,58 para 10,54 mmHg. A fração de ejeção apresentou aumento significativo após o 7º pós-operatório. Insuficiência aórtica residual esteve presente em 30,30% dos pacientes. Ocorreu uma complicação vascular periférica e um caso de bloqueio atrioventricular total. Um paciente apresentou acidente vascular cerebral. A mortalidade em 30 dias foi de 18,18%. CONCLUSÃO: O implante transapical de valva aórtica transcateter é procedimento seguro e com resultados de médio prazo satisfatórios. São necessários estudos de longo prazo com maior poder amostral no intuito de determinar resultado hemodinâmico, qualidade de vida e sobrevida em longo prazo.


OBJECTIVE: Aortic valve replacement is a routine procedure with acceptable risk, but in some cases, such risk can justify contraindication. Minimally invasive transcatheter aortic valve implantation has emerged as an alternative, with lower morbidity and mortality. The aim of this study was clinical, safety and efficacy assessment. METHODS: Thirty-three high risk patients underwent transcatheter balloon expandable aortic valve implantation. Mean Logistic EuroScore risk was 39.30% and STS score 30.28%. Eight patients presented with dysfunctional bioprosthesis, remaining ones presented calcified aortic stenosis. Procedures were performed in a hybrid OR under fluoroscopic and echocardiography guidance. Using a left minithoracotomy the prosthesis were implanted trough the ventricular apex under rapid ventricular pacing or hemorrhagic shock. Echocardiographic and angiographic controls were performed. RESULTS: Implant was feasible in 30 cases. Three conversions occured. There was only one case of operative death. Median transvalvular aortic gradient reduced from 43.58 mmHg to 10.54 mmHg. Left ventricular function improved in the first 7 postoperative days. Paravalvular aortic regurgitation was mild and present in 30.30%. One case presented major vascular complication and another one permanent pacemaker implant. One major stroke case occurred. Overall 30-day mortality was 18.18%. CONCLUSION: The transapical implantation of catheter mounted bioprosthesis is a safe procedure with acceptable midterm results. Long term follow-up with increased sample power is mandatory in order to access hemodynamic, life quality and survival.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Calcinosis/surgery , Cardiac Catheterization/adverse effects , Heart Valve Prosthesis Implantation/methods , Aortic Valve Stenosis/physiopathology , Brazil , Calcinosis/physiopathology , Feasibility Studies , Cardiac Catheterization/methods , Heart Valve Prosthesis Implantation/mortality , Kaplan-Meier Estimate , Risk Assessment/methods , Treatment Outcome
10.
Rev Bras Cir Cardiovasc ; 25(3): 293-302, 2010.
Article in English, Portuguese | MEDLINE | ID: mdl-21103736

ABSTRACT

OBJECTIVE: The aortic valve replacement is a routine procedure with acceptable risk, but in some cases, such a risk can justify contraindication. The minimally invasive transcatheter aortic valve implantation has been viable, with lower morbidity and mortality. The aim of this study was to develop a national catheter-mounted aortic bioprosthesis for the aortic position implant. METHODS: After animal studies, 14 patients with high EuroSCORE underwent transcatheter aortic valve implantation. Median Logistic EuroSCORE was 43.7%. Four patients presented with dysfunctional bioprosthesis, remaining ones presented calcified aortic stenosis. All patients presented symptoms. Procedures were performed in a hybrid OR under fluoroscopic and echocardiography guidance. Using a left minithoracotomy the prosthesis was implanted through the ventricular apex under ventricular pacing or hemorrhagic shock, after aortic valvoplasty. Echocardiograph and angiograph controls were performed, and the patients were referred to ICU. RESULTS: Implant was feasible in 13 cases. There were no intra-operative deaths. Median peak transvalvular aortic gradient reduced to 25.0 mmHg, and left ventricular function improved in the first seven post-operative days. Paravalvular aortic regurgitation was mild and present in 71%. No definitive pacemaker was needed. There was no peripheral vascular complication. Overall mortality was 42%. CONCLUSION: The transapical implantation of cathetermounted bioprosthesis was a feasible procedure. Long term follow-up is mandatory in order to access efficacy and indications.


Subject(s)
Aortic Valve Stenosis/surgery , Heart Valve Prosthesis Implantation/methods , Thoracotomy/methods , Adult , Aged , Aged, 80 and over , Aortography , Cardiac Catheterization/methods , Female , Heart Valve Prosthesis Implantation/mortality , Humans , Male , Middle Aged , Treatment Outcome
11.
Rev. bras. cir. cardiovasc ; 25(3): 293-302, jul.-set. 2010. ilus, tab
Article in Portuguese | LILACS | ID: lil-564994

ABSTRACT

OBJETIVO: A troca valvar aórtica é procedimento rotineiro com risco aceitável. Em alguns casos, a mortalidade é elevada, levando à contraindicação do procedimento, apesar dos sintomas. O implante minimamente invasivo transcateter de valva aórtica parece ser uma alternativa, reduzindo a morbi-mortalidade. O objetivo deste estudo foi o desenvolvimento e implante de nova prótese para implante transcateter. MÉTODOS: Após desenvolvimento em animais, uma prótese transcateter, balão-expansível foi utilizada em 14 casos de alto risco. O EuroSCORE médio foi de 43,7 por cento. Quatro pacientes apresentavam disfunção de biopróteses e o restante, estenose aórtica calcificada. Todos os pacientes eram sintomáticos. Os procedimentos foram realizados em ambiente cirúrgico híbrido, sob controle ecocardiográfico e fluoroscópico. Com o uso de minitoracotomia esquerda, as próteses foram implantadas através do ápice ventricular, sob estimulação ventricular de alta frequência ou choque hemorrágico controlado, após valvoplastia aórtica. Foram realizados controles clínicos e ecocardiográficos seriados. RESULTADOS: A correta liberação da prótese foi possível em 13 casos. Uma conversão ocorreu. Não houve mortalidade operatória. O gradiente de pico médio pós-implante foi de 25 mmHg. A fração de ejeção apresentou aumento significativo após o 7º pós-operatório. Insuficiência aórtica residual não significativa esteve presente em 71 por cento dos casos, nenhuma significativa. Não ocorreu complicação vascular periférica. Não houve necessidade de marcapasso definitivo. Um caso de acidente vascular cerebral ocorreu. A mortalidade geral foi de 42 por cento. CONCLUSÃO: O implante transapical de valva aórtica transcateter é um procedimento possível com esta nova prótese. O comportamento hemodinâmico foi satisfatório. São necessários estudos de longo prazo e com maior poder amostral, no intuito de determinar a real eficácia e indicação do procedimento alternativo.


OBJECTIVE: The aortic valve replacement is a routine procedure with acceptable risk, but in some cases, such a risk can justify contraindication. The minimally invasive transcatheter aortic valve implantation has been viable, with lower morbidity and mortality. The aim of this study was to develop a national catheter-mounted aortic bioprosthesis for the aortic position implant. METHODS: After animal studies, 14 patients with high EuroSCORE underwent transcatheter aortic valve implantation. Median Logistic EuroSCORE was 43.7 percent. Four patients presented with dysfunctional bioprosthesis, remaining ones presented calcified aortic stenosis. All patients presented symptoms. Procedures were performed in a hybrid OR under fluoroscopic and echocardiography guidance. Using a left minithoracotomy the prosthesis was implanted through the ventricular apex under ventricular pacing or hemorrhagic shock, after aortic valvoplasty. Echocardiograph and angiograph controls were performed, and the patients were referred to ICU. RESULTS: Implant was feasible in 13 cases. There were no intra-operative deaths. Median peak transvalvular aortic gradient reduced to 25.0 mmHg, and left ventricular function improved in the first seven post-operative days. Paravalvular aortic regurgitation was mild and present in 71 percent. No definitive pacemaker was needed. There was no peripheral vascular complication. Overall mortality was 42 percent. CONCLUSION: The transapical implantation of cathetermounted bioprosthesis was a feasible procedure. Long term follow-up is mandatory in order to access efficacy and indications.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Aortic Valve Stenosis/surgery , Heart Valve Prosthesis Implantation/methods , Thoracotomy/methods , Aortography , Cardiac Catheterization/methods , Heart Valve Prosthesis Implantation/mortality , Treatment Outcome
12.
Rev Bras Cir Cardiovasc ; 24(2): 233-8, 2009.
Article in English | MEDLINE | ID: mdl-19768304

ABSTRACT

OBJECTIVE: The aortic valve replacement is a routine procedure, and involves replacement of the native valve/prosthesis. In most of the patients who undergo such procedure the risk is acceptable, but in some cases, such risk can justify contraindication. The minimally invasive transcatheter aortic valve implantation without cardiopulmonary bypass (CPB) has been shown to be viable, with lower morbidity and mortality. The aim of this study was to develop a catheter-mounted aortic bioprosthesis for implantation without CPB. METHODS: After developing in animals, three patients with high EuroSCORE underwent implantation. Case 1: patients with bioprosthesis dysfunction; Case 2: severe aortic stenosis; Case 3: dysfunction of aortic bioprosthesis. After minithoracotomy and under echocardiographic and fluoroscopic control, a balloon catheter was placed on aortic position and inflated. After, a second balloon with valved endoprosthesis was positioned and released under high ventricular rate. Echocardiographic and angiographic controls were performed and the patients were referred to ICU. RESULTS: In the first case, implantation without CPB was possible with appropriate results. The patient evolved with improvement of ventricular function. After, this patient developed bronchopneumonia, tracheoesophageal fistula and died due to mediastinitis. Autopsy confirmed proper valve positioning and leaflets preservation. The second case showed the device migration after inflation of the balloon, with the need for urgent median sternotomy, CPB and conventional valve replacement. This patient evolved well and was discharged from the ICU on the 14th postoperative day without complications. This patient developed respiratory infection, septic shock and died on the 60th postoperative day. The patient from the third case underwent successful implantation. CONCLUSION: The off-pump transapical implantation of catheter-mounted bioprosthesis was shown to be a feasible procedure. Technical details and learning curve require further discussion.


Subject(s)
Aortic Valve Stenosis/therapy , Aortic Valve/surgery , Bioprosthesis , Catheterization/instrumentation , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis , Aged, 80 and over , Cardiopulmonary Bypass , Fatal Outcome , Female , Heart Valve Prosthesis Implantation/adverse effects , Humans , Male , Middle Aged , Prosthesis Design , Prosthesis Failure , Reoperation , Risk Assessment
13.
Rev. bras. cir. cardiovasc ; 24(2): 233-238, abr.-jun. 2009. ilus
Article in English, Portuguese | LILACS | ID: lil-525563

ABSTRACT

OBJETIVO: A troca valvar aórtica é procedimento rotineiro, envolve substituição da valva nativa/prótese. Na maioria destes pacientes o risco é aceitável, porém, em alguns casos, o risco predito pode justificar contra-indicação. O implante de valva aórtica minimamente invasivo transcateter e sem circulação extracorpórea (CEC) tem se mostrado viável, com menor morbi-mortalidade. O objetivo deste trabalho foi desenvolver bioprótese aórtica, montada em cateter, para implante sem CEC. MÉTODOS: Após desenvolvimento em animais, três pacientes com EuroSCORE elevado foram submetidos ao implante. Caso 1: portador de bioprótese com disfunção; Caso 2: estenose aórtica grave; Caso 3: disfunção de bioprótese aórtica. Após minitoracotomia e sob controle ecocardiográfico e fluoroscópico, cateter-balão foi posicionado sobre posição aórtica e insuflado. Após, segundo cateter-balão, com endoprótese valvada, foi posicionado e liberado sob alta frequência ventricular. Controles angiográficos e ecocardiográficos foram realizados e pacientes encaminhados para UTI. RESULTADOS: No primeiro caso foi possível implante sem CEC com resultados adequados. Evoluiu com melhora da função ventricular. Cursou com broncopneumonia, fístula traqueo-esofágica e óbito por mediastinite. Necropsia confirmou bom posicionamento valvar e preservação dos folhetos. O segundo caso apresentou migração do dispositivo após insuflação do balão, necessidade de esternotomia mediana de urgência, CEC e troca valvar convencional. O paciente evoluiu bem, recebendo alta da UTI 14 dias após procedimento e sem complicações. Cursou com infecção respiratória, choque séptico e óbito no 60º pós-operatório. O terceiro caso foi submetido a implante com sucesso. CONCLUSÃO: O implante de bioprótese transapical montada em cateter sem CEC mostrou ser procedimento factível. Detalhes técnicos e a curva de aprendizado demandam discussão.


OBJECTIVE: The aortic valve replacement is a routine procedure, and involves replacement of the native valve/prosthesis. In most of the patients who undergo such procedure the risk is acceptable, but in some cases, such risk can justify contraindication. The minimally invasive transcatheter aortic valve implantation without cardiopulmonary bypass (CPB) has been shown to be viable, with lower morbidity and mortality. The aim of this study was to develop a catheter-mounted aortic bioprosthesis for implantation without CPB. METHODS: After developing in animals, three patients with high EuroSCORE underwent implantation. Case 1: patients with bioprosthesis dysfunction; Case 2: severe aortic stenosis; Case 3: dysfunction of aortic bioprosthesis. After minithoracotomy and under echocardiographic and fluoroscopic control, a balloon catheter was placed on aortic position and inflated. After, a second balloon with valved endoprosthesis was positioned and released under high ventricular rate. Echocardiographic and angiographic controls were performed and the patients were referred to ICU. RESULTS: In the first case, implantation without CPB was possible with appropriate results. The patient evolved with improvement of ventricular function. After, this patient developed bronchopneumonia, tracheoesophageal fistula and died due to mediastinitis. Autopsy confirmed proper valve positioning and leaflets preservation. The second case showed the device migration after inflation of the balloon, with the need for urgent median sternotomy, CPB and conventional valve replacement. This patient evolved well and was discharged from the ICU on the 14th postoperative day without complications. This patient developed respiratory infection, septic shock and died on the 60th postoperative day. The patient from the third case underwent successful implantation. CONCLUSION: The off-pump transapical implantation of catheter-mounted bioprosthesis was shown to be a feasible ...


Subject(s)
Aged, 80 and over , Female , Humans , Male , Middle Aged , Aortic Valve Stenosis/therapy , Aortic Valve/surgery , Bioprosthesis , /instrumentation , Heart Valve Prosthesis , Heart Valve Prosthesis Implantation/methods , Cardiopulmonary Bypass , Fatal Outcome , Heart Valve Prosthesis Implantation/adverse effects , Prosthesis Design , Prosthesis Failure , Reoperation , Risk Assessment
14.
Ann Thorac Surg ; 87(5): 1360-5, 2009 May.
Article in English | MEDLINE | ID: mdl-19379864

ABSTRACT

BACKGROUND: Thoracic endovascular aortic repair of type B aortic dissection is a therapeutic option for selected patients. However, late outcomes of this intervention are virtually unknown, and the series already published are heterogenous regarding demographics, indications, and type of devices. METHODS: From 1997 to 2004, 106 patients exclusively with classic complicated or symptomatic type B aortic dissection were treated with thoracic endovascular aortic repair, using the same device. We present in-hospital outcomes and late follow-up for 73 patients. RESULTS: Technical success was achieved for 99% of patients, and the clinical success rate was 83% (exclusion of the false lumen, no early death or surgical conversion). In-hospital death occurred in 5 patients, 2 of them after surgical conversion. Three patients required urgent surgical conversion. Neurologic complications occurred in 5 patients (1 case of paraplegia). The average time of follow-up was 35.9 +/- 28.5 months. During follow-up, 37% of patients initially successfully treated reached a failure criterion (new endovascular or surgical intervention in the same aortic segment or death due to aortic or unknown cause). Kaplan-Meier curve showed late survival rates higher than 80% in 2 years. CONCLUSIONS: Patients with both acute and chronic type B aortic dissection had excellent initial results with thoracic endovascular aortic repair. Although event-free survival rates decreased gradually with time owing to the frequent need for new interventions, survival curves were comparable to those for less complex patients undergoing clinical or surgical treatment. Randomized studies are required to establish the actual benefit of this new approach.


Subject(s)
Aortic Aneurysm/surgery , Aortic Dissection/surgery , Acute Disease , Aortic Dissection/mortality , Aortic Aneurysm/mortality , Chronic Disease , Female , Follow-Up Studies , Hospital Mortality , Humans , Male , Myocardial Revascularization/methods , Myocardial Revascularization/mortality , Retrospective Studies , Survival Rate , Survivors , Treatment Failure , Treatment Outcome
15.
Arq Bras Cardiol ; 91(2): e25-7, 2008 Aug.
Article in English, Portuguese | MEDLINE | ID: mdl-18709253

ABSTRACT

The patent ductus arteriosus (PDA) is a common type of congenital heart defect and its correction is simple when performed early in life. Surgery is performed using stitches or clips. In adults, the anomaly can lead to pulmonary hypertension and ventricular dysfunction. Surgery in adults is controversial and high-risk. This report describes an alternative endovascular approach in an adult patient.


Subject(s)
Cardiac Catheterization/methods , Ductus Arteriosus, Patent/surgery , Prosthesis Implantation/methods , Adult , Ductus Arteriosus, Patent/diagnosis , Female , Humans , Treatment Outcome
16.
Arq. bras. cardiol ; 91(2): e17-e19, ago. 2008. ilus
Article in English, Portuguese | LILACS | ID: lil-488903

ABSTRACT

A persistência do canal arterial (PCA) é uma anomalia relativamente freqüente e de simples correção. A correção envolve a ligadura do ducto com ou sem a sua secção. A anomalia em adultos pode provocar hipertensão pulmonar persistente e disfunção ventricular. A correção em adultos é controversa e de maior risco. Um caso de correção endovascular com acesso intra-abdominal da PCA em adulto é descrito.


The patent ductus arteriosus (PDA) is a common type of congenital heart defect and its correction is simple when performed early in life. Surgery is performed using stitches or clips. In adults, the anomaly can lead to pulmonary hypertension and ventricular dysfunction. Surgery in adults is controversial and high-risk. This report describes an alternative endovascular approach in an adult patient.


Subject(s)
Adult , Female , Humans , Ductus Arteriosus, Patent/surgery , Cardiac Catheterization/methods , Prosthesis Implantation/methods , Ductus Arteriosus, Patent/diagnosis , Treatment Outcome
17.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 16(3): 127-137, jul.-set. 2006. tab
Article in Portuguese | LILACS | ID: lil-439240

ABSTRACT

A importância crescente das doenças cardiovasculares como principal causa de morbidade e mortalidade é conhecida. A manifestação inicial da doença pode ser devastadora. O conhecimento de alguns fatores de risco, que, quando presentes, tornam a pessoa mais vulnerável à aquisição da doença, constitui os alicerces da profilaxia das doenças cardiovasculares. O exame clínico é parte essencial do check-up cardiológico e aliado à análise dos fatores de risco seleciona os exames complementares adequados. A partir do exame clínico e dos fatores de risco presentes utiliza-se o modelo de previsão de eventos de Framingham; para aqueles mais vulneráveis, adota-se uma atitude mais enérgica sobre os fatores de risco, devendo, quando necessário, ser indicada terapêutcia medicamentosa.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Cardiovascular Diseases/complications , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/mortality , Risk Factors , Stroke/complications , Stroke/diagnosis , Stroke/mortality , Rheumatic Diseases/complications , Rheumatic Diseases/diagnosis , Rheumatic Diseases/mortality , Hypertension/complications , Hypertension/diagnosis , Hypertension/mortality
18.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 15(5): 362-368, set.-out. 2005. ilus
Article in Portuguese | LILACS | ID: lil-433971

ABSTRACT

O tratamento das doenças da aorta ainda constituem desafio médico não só por sua complexidade como também pela complexidade da população por ela acometida. O tratamento cirúrgico dessas doenças, que se acompanha de altas taxas de mortalidade e de morbidade, fica reservado para os pacientes com dilatação aneurismática, com sinais de rotura ou rotura eminente e com isquemia em orgãos alvo. A introdução da terapia endovascular com implante de endopróteses surge como alternativa ao tratamento cirúrgico em casos selecionados e teria como um de seus principais objetivos diminuir as taxas de complicações asociadas ao tratamento cirúrgico. A seleção de pacientes para as intervenções endovasculares seguem critérios clínicos e anatômicos bem definidos. Os critérios clínicos são os mesmos de indicação da cirurgia clássica. Os critérios anatômicos estabelecem: que o processo patológico esteja restrito à aorta ascendente, que existam colos proximais e distais para uma boa aterrissagem da endoprótese, e que haja uma via de acesso adequada para a progressão dos dispositivos, principalmente no que diz respeito ao sistema ilíaco femoral. O procedimento pode ser realizado na sala de hemodinâmica e frequentemente sob anestesia regional. As taxas de sucesso com esse procedimento estão em torno de 80 a 90 por cento, com taxas de complicações aceitáveis. O seguimento dos pacientes com exames de imagem deve ser periódico, tendo-se em mente a natureza progressiva das doenças da aorta e o fato de essa modalidade terapêutica ainda não ter sua evolução completamente avaliada.


Subject(s)
Male , Female , Humans , Aneurysm/surgery , Aneurysm/complications , Aneurysm/diagnosis , Stents
19.
Arq Bras Cardiol ; 84(6): 457-60, 2005 Jun.
Article in Portuguese | MEDLINE | ID: mdl-16007310

ABSTRACT

OBJECTIVE: To assess the effects of the relief of the mitral stenosis by percutaneous ballon valvotomy in the function of the left atrial appendage. METHODS: Twelve patients with symptomatic mitral stenosis, in sinus rhythm, were studied. They were submitted to the transesophageal echocardiogram before and after effective percutaneous ballon valvotomy. Concerning the left atrial appendage, the peak flow velocities and the respective integral of the anterograde and retrograde flow, in addition to the ejection fraction calculated through the planimetry of the area of that structure, were analyzed at the pulsatile Doppler. RESULTS: There was a significant increase of the anterograde flow velocity of the left atrial appendage after percutaneous ballon valvotomy (pre: mean of 0.30 m/s; post: mean of 0.47 m/s; p<0.05) and their respective integrals. The same happened with the retrograde flow velocity (pre: mean of 0.35 m/s, post: mean of 0.53 m/s; p<0.05). There was a tendency of increase of the ejection fraction of the left atrial appendage after the procedure (pre: mean of 20%, post: mean of 31%; p=0.08). CONCLUSION: The effective opening of the stenosed mitral orifice resulting from the percutaneous ballon valvotomy determined an improvement of the flow pattern of the left atrial appendage, which can potentially contribute for the reduction of the embolic risk.


Subject(s)
Atrial Appendage/physiopathology , Atrial Function, Left/physiology , Catheter Ablation , Catheterization , Echocardiography, Transesophageal , Mitral Valve Stenosis/therapy , Adolescent , Adult , Atrial Appendage/diagnostic imaging , Blood Flow Velocity , Echocardiography, Doppler , Female , Humans , Male , Mitral Valve Stenosis/diagnostic imaging , Mitral Valve Stenosis/physiopathology
20.
Arq. bras. cardiol ; 84(6): 457-460, jun. 2005. ilus
Article in Portuguese | LILACS | ID: lil-420006

ABSTRACT

OBJETIVO: Avaliar os efeitos da abertura efetiva da valva mitral estenótica através da valvotomia percutânea por cateter balão na funcão do apêndice atrial esquerdo. MÉTODOS: Foram estudados 12 pacientes com estenose mitral sintomática, em ritmo sinusal, submetidos ao ecocardiograma transesofágico antes e após valvotomia percutânea por cateter balão efetiva. Em relacão ao apêndice atrial esquerdo, foram analisadas ao Doppler pulsátil as velocidades máximas e respectivas integrais dos fluxos anterógrado e retrógrado, além da fracão de ejecão calculada pela planimetria da área desta estrutura. RESULTADOS: Houve aumento significante das velocidades de fluxo anterógrado do apêndice atrial esquerdo após valvotomia percutânea por cateter balão (pré: média de 0,30 m/s; pós: média de 0,47 m/s; p<0,05) e de suas respectivas integrais. O mesmo ocorreu com as velocidades de fluxo retrógrado (pré: média de 0,35 m/s, pós: média de 0,53 m/s; p<0,05). Houve tendência de aumento da fracão de ejecão do apêndice atrial esquerdo após o procedimento (pré: média de 20 por cento, pós: média de 31 por cento; p=0,08). CONCLUSAO: A abertura efetiva do orifício mitral estenosado decorrente da valvotomia percutânea por cateter balão determinou melhora do padrão de fluxo do apêndice atrial esquerdo, o que potencialmente pode contribuir para reducão do risco embólico.


Subject(s)
Adult , Middle Aged , Humans , Male , Female , Atrial Function, Left/physiology , Chagas Cardiomyopathy/physiopathology , Blood Flow Velocity , Chagas Cardiomyopathy , Echocardiography, Doppler , Echocardiography, Transesophageal , Heart Atria/physiopathology , Heart Atria
SELECTION OF CITATIONS
SEARCH DETAIL
...